| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology, Vol 108, 2017-2018, Copyright © 1981 by Endocrine Society
ARTICLES |
DA Van Vugt, PW Sylvester, CF Aylsworth and J Meites
The ability of dynorphin and beta h-endorphin (beta h-EP) to stimulate prolactin (PRL) release in male rats was examined. Rats were injected intraventricularly with either 1 or 10 microgram dynorphin, 1 or 10 microgram beta h-EP, 10 microgram dynorphin together with 20 microgram naloxone (NAL), or an equivalent volume (13 microliter) of saline. Dynorphin caused a dose-dependent release of PRL which was significant 10 min after injection but not at later sampling times. beta h-EP also increased serum PRL levels and maintained elevated PRL levels for at least 60 min. NAL, a specific opiate antagonist, completely blocked dynorphin-induced PRL release. These results indicate that dynorphin is a potent stimulator of PRL release, but its stimulatory activity is transient relative to the activity exhibited by beta h-EP. Furthermore, dynorphin's action is specific since NAL completely blocked dynorphin induced PRL release.
This article has been cited by other articles:
![]() |
M. J. Kreek, J. Schluger, L. Borg, M. Gunduz, and A. Ho Dynorphin A1-13 Causes Elevation of Serum Levels of Prolactin Through an Opioid Receptor Mechanism in Humans: Gender Differences and Implications for Modulation of Dopaminergic Tone in the Treatment of Addictions J. Pharmacol. Exp. Ther., January 1, 1999; 288(1): 260 - 269. [Abstract] [Full Text] |
||||
![]() |
D. Sarkar, P. Gottschall, and J Meites Damage to hypothalamic dopaminergic neurons is associated with development of prolactin-secreting pituitary tumors Science, November 12, 1982; 218(4573): 684 - 686. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |